Capital City Trust’s iShares Biotechnology ETF IBB Stock Holding History

Capital City Trust’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-180	Closed	-$10K	–	145
2013 Q2	$10K	Buy	+180	New	+$10.4K	﹤0.01%	175

Other funds holding IBB

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital City Trust's IBB Position: Q3 2013 in Review

Capital City Trust sold out of iShares Biotechnology ETF (IBB) in Q3 2013, closing a stake of 180 shares — an estimated $10K sold.

Capital City Trust first reported a position in IBB in Q2 2013 and held it in 1 quarter. The position peaked at $10K in Q2 2013. 253 funds tracked by Wall St. Rank hold IBB as of Q3 2013.

Capital City Trust reported no remaining iShares Biotechnology ETF position as of Q3 2013 after selling out during the quarter.
Capital City Trust sold 180 iShares Biotechnology ETF shares in Q3 2013, an estimated $10K.
Capital City Trust first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 1 quarter.
Capital City Trust's iShares Biotechnology ETF position peaked at $10K in Q2 2013.
253 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2013.

Based on Capital City Trust's 13F filing for Q3 2013, filed 12 Nov 2013.